As reported in The Lancet by Viola Poeschel, MD, and colleagues, the phase III FLYER trial has shown noninferiority of progression-free survival with four vs six cycles of cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) in combination with six doses of rituximab in patients with aggressive B-cell lymphoma with a favorable prognosis.

Interim analysis of the phase I/II KEYNOTE-051 trial, reported in The Lancet Oncology by Geoerger et al, indicated minimal activity of pembrolizumab in pediatric patients with programmed cell death ligand 1 (PD-L1)-positive advanced, relapsed, or refractory solid tumors; however, activity was observed in pediatric patients with relapsed or refractory Hodgkin lymphoma.

Primary mediastinal B-cell lymphoma is an uncommon but distinct clinicopathologic variant of diffuse large B-cell lymphoma (DLBCL) that typically presents...

The investigational bispecific antibody mosunetuzumab is showing activity in preliminary studies of patients with non-Hodgkin lymphoma (NHL), including those who are refractory to or relapsed after third-line chimeric antigen receptor (CAR) T-cell therapy. If preliminary findings are validated by further study, mosunetuzumab, and perhaps other bispecific antibodies in development, may present an option after CAR T-cell therapy for patients with B-cell lymphomas and leukemias who no longer have treatment options.

Most people diagnosed with early-stage, or limited, diffuse large B-cell lymphoma (DLBCL) may be able to safely skip radiation treatment after a clear positron-emission tomography (PET) scan, according to new clinical trial results from SWOG presented by Persky et al at the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition.